341: NIH funding cuts, a U.S. brain drain, and bold claims from AI drug developers
We bring on biotech reporter Jonathan Wosen to discuss the NIH's decision to dramatically cut funding for overhead costs paid to research institutions and the potential implications for U.S. biomedica...
13 Feb 202526min
340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug
We bring on our colleague Jason Mast to discuss the dramatic downturn in the once-swaggering field of CRISPR gene editing. We also talk about the advancement of RFK Jr.'s nomination to be HHS secretar...
6 Feb 202534min
339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad
Our colleague Rachel Cohrs Zhang joins us to break down RFK Jr.’s confirmation hearings, including some contentious questions about vaccines and autism from Sens. Bill Cassidy (R-La.) and Bernie Sande...
30 Jan 202534min
338: Chinese biotechs, a WHO departure, and post-JPM thoughts
We go over our closing thoughts from the J.P. Morgan Healthcare Conference, including the chatter around Chinese drugs and a surprise run-in with a past cohost. Then, STAT's infectious disease reporte...
23 Jan 202533min
337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss
We're live at the J.P Morgan Healthcare Conference in San Francisco! We bring on Eli Lilly CEO Dave Ricks for a wide-ranging conversation about his views on the incoming Trump administration, the effe...
15 Jan 202558min
336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study
We chat about how pharmaceutical companies are navigating a looming patent cliff. We also talk about yet another obesity startup and a failed study from Google’s secretive anti-aging company Calico.
9 Jan 202533min
335: A deep dive on Makary, Vertex's pain data, & 2025 predictions
STAT's FDA reporter Lizzy Lawrence joins us to discuss her profile of Marty Makary, Trump's nominee for FDA commissioner. Then, we discuss the results of Vertex's latest pain drug trial, the medicatio...
19 Dec 202433min
334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children
Washington correspondent John Wilkerson joins to discuss why drugmakers have not lobbied against Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services, despite his rep...
12 Dec 202434min
